Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.

Blackard JT, Kong L, Rouster SD, Karns R, Horn PS, Kottilil S, Shata MT, Sherman KE.

PLoS One. 2019 Oct 29;14(10):e0224523. doi: 10.1371/journal.pone.0224523. eCollection 2019.

2.

HIV and the liver.

Sherman KE, Peters MG, Thomas DL.

Top Antivir Med. 2019 Sep/Oct;27(3):101-110.

3.

In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.

Blackard JT, Kwara A, Sherman KE.

J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30418-0. doi: 10.1016/j.jhep.2019.07.010. [Epub ahead of print] No abstract available.

PMID:
31564447
4.

Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV.

Farooq PD, Sherman KE.

Curr HIV/AIDS Rep. 2019 Oct;16(5):395-403. doi: 10.1007/s11904-019-00461-6. Review.

PMID:
31468298
5.

Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index.

Sherman KE, Abdel-Hameed EA, Ehman RL, Rouster SD, Campa A, Martinez SS, Huang Y, Zarini GG, Hernandez J, Teeman C, Tamargo J, Liu Q, Mandler R, Baum MK.

Dig Dis Sci. 2019 Aug 29. doi: 10.1007/s10620-019-05815-z. [Epub ahead of print]

PMID:
31468264
6.

Hepatitis C virus antigens enzyme immunoassay for one-step diagnosis of hepatitis C virus coinfection in human immunodeficiency virus infected individuals.

Hu KQ, Cui W, Rouster SD, Sherman KE.

World J Hepatol. 2019 May 27;11(5):442-449. doi: 10.4254/wjh.v11.i5.442.

7.

Fatty liver disease in persons with HIV infection.

Seth A, Sherman KE.

Top Antivir Med. 2019 May;27(2):75-82.

8.

Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool.

Dao A, Cuffy M, Kaiser TE, Loethen A, Cafardi J, Luckett K, Rike AH, Cardi M, Alloway RR, Govil A, Diwan T, Sherman KE, Shah SA, Woodle ES.

Clin Transplant. 2019 Jul;33(7):e13598. doi: 10.1111/ctr.13598. Epub 2019 Jun 5.

PMID:
31104346
9.

Zika virus replication and cytopathic effects in liver cells.

Sherman KE, Rouster SD, Kong LX, Aliota MT, Blackard JT, Dean GE.

PLoS One. 2019 Mar 20;14(3):e0214016. doi: 10.1371/journal.pone.0214016. eCollection 2019.

10.

HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.

Shata MTM, Abdel-Hameed EA, Rouster SD, Yu L, Liang M, Song E, Esser MT, Shire N, Sherman KE.

Pathog Immun. 2019;4(1):39-65. doi: 10.20411/pai.v4i1.267. Epub 2019 Feb 13.

11.

Clinical features and determinants of chronicity in hepatitis E virus infection.

Narayanan S, Abutaleb A, Sherman KE, Kottilil S.

J Viral Hepat. 2019 Apr;26(4):414-421. doi: 10.1111/jvh.13059. Epub 2019 Feb 5. Review.

PMID:
30636092
12.

Transplanting Hepatitis C Virus-Infected or Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients.

Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE.

Ann Intern Med. 2018 Dec 18;169(12):898-899. doi: 10.7326/L18-0566. No abstract available.

PMID:
30557435
13.

Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.

Foster GR, Dore GJ, Wang S, Grebely J, Sherman KE, Baumgarten A, Conway B, Jackson D, Asselah T, Gschwantler M, Tomasiewicz K, Aguilar H, Asatryan A, Hu Y, Mensa FJ.

Drug Alcohol Depend. 2019 Jan 1;194:487-494. doi: 10.1016/j.drugalcdep.2018.11.007. Epub 2018 Nov 24.

PMID:
30529905
14.

Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.

Sherman KE, Abdel-Hameed E, Rouster SD, Shata MTM, Blackard JT, Safaie P, Kroner B, Preiss L, Horn PS, Kottilil S.

Clin Infect Dis. 2019 May 17;68(11):1911-1918. doi: 10.1093/cid/ciy807.

15.

A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.

Abutaleb A, Sherman KE.

Hepatol Int. 2018 Nov;12(6):500-509. doi: 10.1007/s12072-018-9896-4. Epub 2018 Sep 20. Review.

16.

PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals.

Sherman KE, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA; ACTG 5294 BIRTH Study Team.

Dig Dis Sci. 2018 Nov;63(11):2969-2974. doi: 10.1007/s10620-018-5278-y. Epub 2018 Sep 14.

17.

Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.

Eckman MH, Ward JW, Sherman KE.

Clin Gastroenterol Hepatol. 2019 Apr;17(5):930-939.e9. doi: 10.1016/j.cgh.2018.08.080. Epub 2018 Sep 8.

PMID:
30201597
18.

Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis.

Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE.

Ann Intern Med. 2018 Aug 21;169(4):214-223. doi: 10.7326/M17-3088. Epub 2018 Jul 10.

PMID:
29987322
19.

Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical?

Anwar N, Sherman KE.

J Viral Hepat. 2018 Oct;25(10):1110-1115. doi: 10.1111/jvh.12962. Epub 2018 Aug 14. Review.

PMID:
29968277
20.

Zika Virus Exposure in an HIV-Infected Cohort in Ghana.

Sherman KE, Rouster SD, Kong LX, Shata TM, Archampong T, Kwara A, Aliota MT, Blackard JT.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):e35-e38. doi: 10.1097/QAI.0000000000001718. No abstract available.

21.

Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).

Blackard JT, Sherman KE.

Rev Med Virol. 2018 Jul;28(4):e1984. doi: 10.1002/rmv.1984. Epub 2018 May 15. Review.

22.

Hepatitis D diagnostics:Utilization and testing in the United States.

Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE.

Virus Res. 2018 May 2;250:114-117. doi: 10.1016/j.virusres.2018.03.013. Epub 2018 Mar 27.

PMID:
29596839
23.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.

Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M.

Clin Infect Dis. 2018 Sep 14;67(7):1010-1017. doi: 10.1093/cid/ciy220.

24.

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.

Wang GP, Terrault N, Reeves JD, Liu L, Li E, Zhao L, Lim JK, Morelli G, Kuo A, Levitsky J, Sherman KE, Frazier LM, Ramani A, Peter J, Akuskevich L, Fried MW, Nelson DR.

Sci Rep. 2018 Feb 16;8(1):3199. doi: 10.1038/s41598-018-21303-2.

25.

Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients.

Abdel-Hameed EA, Rouster SD, Boyce CL, Zhang X, Biesiada J, Medvedovic M, Sherman KE.

Dig Dis Sci. 2018 Mar;63(3):645-652. doi: 10.1007/s10620-017-4895-1. Epub 2018 Jan 12.

PMID:
29330726
26.

Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

Shive CL, Judge CJ, Clagett B, Kalayjian RC, Osborn M, Sherman KE, Fichtenbaum C, Gandhi RT, Kang M, Popkin DL, Sieg SF, Lederman MM, Rodriguez B, Anthony DD.

Vaccine. 2018 Jan 25;36(4):453-460. doi: 10.1016/j.vaccine.2017.12.018. Epub 2017 Dec 16.

27.

Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients.

Bari K, Luckett K, Kaiser T, Diwan T, Cuffy M, Schoech MR, Safdar K, Blackard JT, Apewokin S, Paterno F, Sherman KE, Zucker SD, Anwar N, Shah SA.

Hepatology. 2018 May;67(5):1673-1682. doi: 10.1002/hep.29704. Epub 2018 Mar 26.

PMID:
29205441
28.

Viral Hepatitis: Knowledge and Treatments for Hepatitis B and C Virus and Associated Transplantation and Neoplasia.

Sherman KE, Shah VH.

Gastroenterology. 2018 Feb;154(3):453-456. doi: 10.1053/j.gastro.2017.10.047. Epub 2017 Nov 14. No abstract available.

PMID:
29154778
29.

Human immunodeficiency virus and liver disease: A comprehensive update.

Sherman KE, Peters MG, Thomas D.

Hepatol Commun. 2017 Nov 6;1(10):987-1001. doi: 10.1002/hep4.1112. eCollection 2017 Dec.

30.

Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, Sherman KE, Butt AA; ACTG A5309s study team.

Drugs R D. 2017 Dec;17(4):557-567. doi: 10.1007/s40268-017-0205-9.

31.

The Enigma of Hepatitis E Virus.

Murrison LB, Sherman KE.

Gastroenterol Hepatol (N Y). 2017 Aug;13(8):484-491.

32.

CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.

Judge CJ, Kostadinova L, Sherman KE, Butt AA, Falck-Ytter Y, Funderburg NT, Landay AL, Lederman MM, Sieg SF, Sandberg JK, Anthony DD.

J Leukoc Biol. 2017 Jul;102(1):171-184. doi: 10.1189/jlb.5A1116-456R. Epub 2017 Apr 11.

33.

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, The Actg Birth Study Team.

World J Hepatol. 2017 Feb 8;9(4):217-223. doi: 10.4254/wjh.v9.i4.217.

34.

Hepatitis delta and HIV infection.

Soriano V, Sherman KE, Barreiro P.

AIDS. 2017 Apr 24;31(7):875-884. doi: 10.1097/QAD.0000000000001424. Review.

PMID:
28121714
35.

Hemophilia Liver Transplantation Observational Study.

Ragni MV, Humar A, Stock PG, Blumberg EA, Eghtesad B, Fung JJ, Stosor V, Nissen N, Wong MT, Sherman KE, Stablein DM, Barin B.

Liver Transpl. 2017 Jun;23(6):762-768. doi: 10.1002/lt.24688.

36.

Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.

Abdel-Hameed EA, Rouster SD, Zhang X, Chen J, Medvedovic M, Goodman ZD, Sherman KE.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):353-358. doi: 10.1097/QAI.0000000000001256.

37.

Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.

Butt AA, Ren Y, Marks K, Shaikh OS, Sherman KE; ERCHIVES study.

Aliment Pharmacol Ther. 2017 Jan;45(1):150-159. doi: 10.1111/apt.13837. Epub 2016 Nov 4.

38.

Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients.

Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, El-Mokhtar MA, Abdelwahab SF, Medhat A, Sherman KE, Shata MT.

Arch Virol. 2016 Nov;161(11):3161-9. doi: 10.1007/s00705-016-3015-4. Epub 2016 Aug 20.

39.

Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.

Butt AA, Yan P, Marks K, Shaikh OS, Sherman KE; ERCHIVES Study Team.

Aliment Pharmacol Ther. 2016 Oct;44(7):728-37. doi: 10.1111/apt.13748. Epub 2016 Jul 26.

40.

Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.

Judge CJ, Sandberg JK, Funderburg NT, Sherman KE, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):258-262.

41.

Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis.

Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, Medhat A, Nassar MI, Sherman KE, Shata MT.

J Med Microbiol. 2016 Aug;65(8):703-12. doi: 10.1099/jmm.0.000272. Epub 2016 May 10.

42.

Recombination among GB virus C (GBV-C) isolates in the United States.

Blackard JT, Ma G, Polen C, DuBois JC, Gast J, Radens CM, Sterling RK, Sherman KE.

J Gen Virol. 2016 Jul;97(7):1537-44. doi: 10.1099/jgv.0.000477. Epub 2016 Apr 11.

43.

Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.

Sherman KE, Ke R, Rouster SD, Abdel-Hameed EA, Park C, Palascak J, Perelson AS.

Haemophilia. 2016 Jul;22(4):543-8. doi: 10.1111/hae.12918. Epub 2016 Mar 3.

44.

Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.

Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study.

Liver Int. 2016 Sep;36(9):1275-83. doi: 10.1111/liv.13103. Epub 2016 Mar 24.

PMID:
26928927
45.

Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.

Lyons MS, Kunnathur VA, Rouster SD, Hart KW, Sperling MI, Fichtenbaum CJ, Sherman KE.

Clin Infect Dis. 2016 May 1;62(9):1066-71. doi: 10.1093/cid/ciw073. Epub 2016 Feb 21.

46.

Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.

Abdel-Hameed EA, Rouster SD, Ji H, Ulm A, Hetta HF, Anwar N, Sherman KE, Shata MT.

Viral Immunol. 2016 May;29(4):252-8. doi: 10.1089/vim.2015.0093. Epub 2016 Feb 17.

47.

Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort.

Campa A, Martinez SS, Sherman KE, Greer JP, Li Y, Garcia S, Stewart T, Ibrahimou B, Williams OD, Baum MK.

J Drug Abuse. 2016;2(4). pii: 27. doi: 10.21767/2471-853X.100036. Epub 2016 Nov 7.

48.

Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.

Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study.

Liver Int. 2016 May;36(5):651-8. doi: 10.1111/liv.13036. Epub 2015 Dec 25.

PMID:
26616353
49.

Epidemiology of Hepatitis C Virus: A Battle on New Frontiers.

Shire NJ, Sherman KE.

Gastroenterol Clin North Am. 2015 Dec;44(4):699-716. doi: 10.1016/j.gtc.2015.07.002. Review.

PMID:
26600215
50.

Management of the Hepatitis B Virus/HIV-Coinfected Patient.

Sherman KE.

Top Antivir Med. 2015 Aug-Sep;23(3):111-4.

Supplemental Content

Loading ...
Support Center